Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings of clinical trials, lisocabtagene maraleucel demonstrated activity in this real-world population. Toxicities were infrequent and manageable, and neither age nor eligibility compromised safety or efficacy.